Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Pembrolizumab in Combination With Chimeric Antigen Receptor Therapy in Patients With Relapsed/Refractory Primary Mediastinal B-cell Lymphoma

NCT05934448 is registered in ClinicalTrials.gov with Jennifer Crombie, MD as lead sponsor.

NCT NCT05934448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05934448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Pembrolizumab in Combination With Chimeric Antigen Receptor Therapy in Patients With Relapsed/Refractory Primary Mediastinal B-cell Lymphoma
Lead sponsor
Jennifer Crombie, MD
Phase
Phase 2
Overall status
Recruiting
Start date
November 15, 2023
Completion date
June 6, 2031
Enrollment
35 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

epstein-barr virus positive diffuse large b-cell lymphoma, primary mediastinal large b cell lymphoma, primary mediastinal large b-cell lymphoma (pmbcl), primary mediastinal large b-cell lymphoma recurrent, primary mediastinal large b-cell lymphoma refractory, t-cell/histiocyte-rich large b-cell lymphoma